Dutasteride, offered under the trade name Avodart, is originally designed for the treatment of benign prostatic hyperplasia (diagnosed along with urination
problems). The preparation refers to the type of DHT-blockers, its action is aimed at inhibiting both types of the enzyme 5-alpha-reductase.
Thus, the drug is demonstrating impressive results in androgenic alopecia treatment, which is confirmed by various surveys (as a result, the high demand
for the medication is partially explained by its non-primary indication for use).
Manufactured by GlaxoSmithKline, the preparation doesn’t have any FDA-approved generic alternatives in the US, unlike Propecia (the drug of a similar scope
As for the hair regrowth capabilities, the preparation has successfully passed two phases of clinical trials as for the efficiency in AGA treatment - as a
result, it’s effectiveness at a dosage of 2.5 mg/day was confirmed.
The third (and final) stage of testing was delayed for many years by the manufacturer, which gave rise to the interested specialists and potential users of
the many different conjectures.
Finally, in April 2013, the third stage of the test at a dosage of 0.5 mg day began with the alleged end in October 2014. In August of 2014 the interim
results after six months of testing were published, which, unfortunately, showed a fairly high percentage of side effects.
Pharmacokinetics and pharmacodynamics of the active ingredient have been studied in multiple tests in a group of 36 healthy men (from 24 to 87 years old)
taking 5mg of the preparation. Between the different age groups was not statistically significant differences in such pharmacokinetic parameters as AUC and
Neither statistically significant differences between the age groups of 50-69 years age and the group over 70 years were found (both groups include the
majority of men with BPH diagnosis).
According to the results of studies published by The Management of Prostatic Obstruction, 0.1 mg of dutasteride reduces the level of DHT the level achieved
with 5.0 mg of finasteride, which equals approximately 70%.
Dosage and administration
The therapeutic and side effects are largely defined by the appointed dosage. The drug is manufactured in the form of a gelatin capsule, containing 0.5mg
dutasteride, which is an average daily dose in benign prostatic hyperplasia treatment course; the dosage sufficient to block 90% of DHT.
The most comprehensive therapeutic effect is achieved with 2.5 - 5mg daily, allowing blocking up to 100% of DHT. This dosage is oftentimes used for AGA
treatment; nevertheless, it greatly increases the risk of adverse reactions.
In case of overdose (a dose 80 times higher than the therapeutic one) no adverse reactions were noted. There’s no specific antidote to dutasteride, and
therefore in case of a suspected overdose symptomatic and supportive treatment would be sufficient to complete the recovery.
The impact on fertility
The active ingredient has a certain impact on qualitative sperm characteristics according to the study that involved the daily dose of 500mcg in 18-52
years old participants.
A long-term, complex 52-weeks demonstrated a partial reduction in total sperm volume, semen amount and sperm motor characteristics by 23%, 26% and 18%
Nevertheless, spermatozoa concentration and their morphological characteristics didn’t change. The violation of the borderline values was observed in 2% of
respondents - the 30% reduction reported.